Jade Biosciences, Inc. presented two posters for JADE101, its investigational anti-APRIL monoclonal antibody for treating IgAN at the American Society of Nephrology Kidney Week 2025. JADE101 is designed to inhibit APRIL, a key driver of IgAN. The drug is currently in Phase 1 trials with promising results, including tolerability and selectivity. The company believes JADE101 has the potential to be a foundational treatment for IgAN patients. Additionally, translational modeling suggests the drug’s efficacy in reducing IgA and proteinuria levels, potentially leading to disease-modifying outcomes. JADE101 offers convenient subcutaneous dosing for patients.

Read more at GlobeNewswire: Jade Biosciences Presents New Data Demonstrating a